Very solid Q2 numbers from $DMTK -- they beat on every metric like billable volumes, assay revenues and total revenues
Billable volumes: +267% YoY
Assay revenues: +349% YoY
Total revenues: +269% YoY
Full year guidance for assay revenues: +171% to 218% YoY
Billable volumes: +267% YoY
Assay revenues: +349% YoY
Total revenues: +269% YoY
Full year guidance for assay revenues: +171% to 218% YoY
I'm very pleased with these results. The numbers are still small but $DMTK is headed in the right direction.
The $DMTK story gets even better moving forward b/c we get the launch of Luminate in 2021 Q4 (estimated) and Carcinome in 2022 Q2 (estimated)
businesswire.com/news/home/2021…
The $DMTK story gets even better moving forward b/c we get the launch of Luminate in 2021 Q4 (estimated) and Carcinome in 2022 Q2 (estimated)
businesswire.com/news/home/2021…
I’ll take the pop 🔥 
Looks like we got a little breakout brewing for $DMTK
• • •
Missing some Tweet in this thread? You can try to
force a refresh
